Biotoxtech Co., Ltd.

KOSDAQ:A086040 Stock Report

Market Cap: ₩50.3b

Biotoxtech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Biotoxtech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth25.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Sep 01

Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their Feet

You may think that with a price-to-sales (or "P/S") ratio of 1.1x Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) is definitely...
Analysis Article • Oct 21

Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their Feet

Biotoxtech Co., Ltd.'s ( KOSDAQ:086040 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...
Analysis Article • May 06

Is Biotoxtech (KOSDAQ:086040) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 28

Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)

Today we will run through one way of estimating the intrinsic value of Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) by...
Analysis Article • Feb 20

Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?

Some Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) shareholders are probably rather concerned to see the share price fall 32...
Analysis Article • Jan 24

Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?

Most readers would already be aware that Biotoxtech's (KOSDAQ:086040) stock increased significantly by 15% over the...
Analysis Article • Dec 27

We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory Earnings

As a general rule, we think profitable companies are less risky than companies that lose money. Having said that...
Analysis Article • Nov 30

Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotoxtech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A086040 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202547,0171,1634,4046,636N/A
9/30/202544,1908792,4924,737N/A
6/30/202543,411-5,828-5,773-3,608N/A
3/31/202543,601-6,612-10,406-8,034N/A
12/31/202441,341-6,427-9,501-7,120N/A
9/30/202438,445-4,410-11,947-11,609N/A
6/30/202434,475-4,943-9,231-8,583N/A
3/31/202433,604-5,419-13,374-12,778N/A
12/31/202332,631-4,878-21,121-16,238N/A
9/30/202334,216-5,408-33,111-16,485N/A
6/30/202336,638-2,487-42,163-11,788N/A
3/31/202337,006199-36,383-3,235N/A
12/31/202237,2921,278-32,094-1,309N/A
9/30/202236,2635,684-19,5442,709N/A
6/30/202235,4615,910-8,2662,006N/A
3/31/202233,9766,462-4,9583,010N/A
12/31/202132,7176,832-3,6104,346N/A
9/30/202131,1203,526-2,9703,917N/A
6/30/202128,5702,6335076,379N/A
3/31/202127,2893,550-2254,638N/A
12/31/202026,4292,6142,0244,564N/A
9/30/202026,3064,2374602,723N/A
6/30/202025,9672,4262,6342,792N/A
3/31/202025,679-1,4141,9022,571N/A
12/31/201925,854-1,4829561,444N/A
9/30/201922,105-4,913N/A3,492N/A
6/30/201923,979-1,548N/A1,869N/A
3/31/201926,63224N/A3,958N/A
12/31/201827,2454,131N/A3,061N/A
9/30/201831,5675,261N/A4,068N/A
6/30/201829,9853,735N/A6,294N/A
3/31/201827,0594,887N/A4,422N/A
12/31/201725,5651,392N/A6,024N/A
9/30/201724,3302,115N/A5,215N/A
6/30/201723,9921,966N/A6,050N/A
3/31/201723,1961,584N/A5,932N/A
12/31/201622,2571,045N/A5,283N/A
9/30/201620,404-1,173N/A2,586N/A
6/30/201618,932-1,942N/A1,038N/A
3/31/201617,932-2,873N/A-608N/A
12/31/201516,676-3,905N/A-798N/A
9/30/201515,384-3,790N/A-1,808N/A
6/30/201515,044-4,539N/A-2,794N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A086040's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A086040's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A086040's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A086040's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A086040's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A086040's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/17 07:25
End of Day Share Price 2026/05/15 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biotoxtech Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Young Ok KimDAOL Investment & Securities Co., Ltd.
Seung-Ho LeeiM Securities